Haematology · Oncology

GELF Criteria for High-Tumor-Burden Follicular Lymphoma calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Any nodal or extranodal tumor mass ≥7 cm (+1)Involvement of ≥3 nodal sites, each with diameter ≥3 cm (+1)B symptoms (fever, night sweats, or weight loss) (+1)Splenic enlargement with infarct or compression (+1)Compression syndrome (ureteral, orbital, GI, etc.) (+1)Leukemic phase (>5.0×10⁹/L circulating malignant cells) (+1)Cytopenias (ANC <1.0 or platelets <100) (+1)

Result

Anyone can run this calculator. Sign in to save, favourite, or send the result.

Low tumor burden (no GELF criteria)

Band: Low tumor burden (no GELF criteria)

Interpretation. Low tumor burden (no GELF criteria)

Suggested management. Low GELF tumor burden — observation may be appropriate if asymptomatic.

GELF Criteria for High-Tumor-Burden Follicular Lymphoma: 0 — Low tumor burden (no GELF criteria). Interpretation: Low tumor burden (no GELF criteria) What to do: Low GELF tumor burden — observation may be appropriate if asymptomatic. Inputs: Any nodal or extranodal tumor mass ≥7 cm (+1): false; Involvement of ≥3 nodal sites, each with diameter ≥3 cm (+1): false; B symptoms (fever, night sweats, or weight loss) (+1): false; Splenic enlargement with infarct or compression (+1): false; Compression syndrome (ureteral, orbital, GI, etc.) (+1): false; Leukemic phase (>5.0×10⁹/L circulating malignant cells) (+1): false; Cytopenias (ANC <1.0 or platelets <100) (+1): false Source: Solal-Celigny P et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. DOI: 10.1056/NEJM199310283291803. PMID: 8232429. Scope: GELF high-tumor-burden follicular lymphoma features include bulky nodal disease (>7 cm or ≥3 sites >3 cm), B symptoms, substantial splenomegaly, compressive/effusion syndromes, leukemic phase, or cytopenias; any criterion denotes high tumor burden used to select systemic therapy. (1993)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

Any nodal or extranodal tumor mass ≥7 cm (+1)
Involvement of ≥3 nodal sites, each with diameter ≥3 cm (+1)
B symptoms (fever, night sweats, or weight loss) (+1)
Splenic enlargement with infarct or compression (+1)
Compression syndrome (ureteral, orbital, GI, etc.) (+1)
Leukemic phase (>5.0×10⁹/L circulating malignant cells) (+1)
Cytopenias (ANC <1.0 or platelets <100) (+1)

Primary source

Solal-Celigny P et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. DOI: 10.1056/NEJM199310283291803. PMID: 8232429. Scope: GELF high-tumor-burden follicular lymphoma features include bulky nodal disease (>7 cm or ≥3 sites >3 cm), B symptoms, substantial splenomegaly, compressive/effusion syndromes, leukemic phase, or cytopenias; any criterion denotes high tumor burden used to select systemic therapy. (1993)

View source